ZYN57939

Research use only, not for human use.

ZYN57939 is RNA polymerase I inhibitor for treating RNA polymerase I- mediated diseases. ZYN57939 showed inhibitory activity with IC50 of 0.855 μM against human HT- 29 cancer cell lines.

ZYN57939 is RNA polymerase I inhibitor for treating RNA polymerase I- mediated diseases. ZYN57939 showed inhibitory activity with IC50 of 0.855 μM against human HT- 29 cancer cell lines.

Cell Viability Assay Cell Line:HR-deficient and PARPi-resistant cancer cells Concentration:0-100 μM Incubation Time:7 days Result:Inhibited the viability of HR-deficient cells and PARPi-resistant cells in a dose-dependent nanner.Cell Cycle Analysis Cell Line:Capan-1 cells Concentration:0.1, 0.3, and 1 μM Incubation Time:24 hours Result:Increased in cells in G2/M, accompanied by a reduction in cell numbers in G1.Western Blot Analysis Cell Line:Capan-1 cells Concentration:1, 5, and 10 μM Incubation Time:24 hours Result:Increased the cleaved caspases 3, 7, and 9 and cleaved PARP in a dose-dependent manner.

Animal Model:BRCA-deficient and PARPi-resistant xenografts in nude mice Dosage:10, 20, and 30 mg/kg Administration:oral administration; twice a week, for 29 days Result:Inhibited tumor growth in a dose-dependent manner.

MTR-106

Cell Cycle/DNA Damage

DNA/RNA Synthesis

RNA polymerase I

——

——

1639357-93-9

524.62

C29H28N6O2S

>98% (HPLC)

DMSO:Insoluble;Water:Insoluble

O=C1C(C(NCC2=NC=C(N=C2)C)=O)=C(SC3=CC=CC=C34)N4C5=NC(C6C[C@@](CN(C)C7)([H])[C@@]7([H])C6)=CC=C15

——

(-20℃)

With Ice Pack

≥ 2 years